MetLife Investment Management’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

MetLife Investment Management’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-66,635	Closed	-$1.24M	–	2943
2022 Q1	$1.24M	Buy	66,635 +23,760	+55%	+$428K	0.01%	1197
2021 Q4	$917K	Buy	42,875 +3,323	+8%	+$65.5K	0.01%	1166
2021 Q3	$731K	Buy	39,552 +4,136	+12%	+$83.3K	0.01%	1293
2021 Q2	$758K	Hold	35,416	–	–	0.01%	1330
2021 Q1	$683K	Buy	+35,416	New	+$624K	0.01%	1347

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MetLife Investment Management's OCDX Position: Q2 2022 in Review

MetLife Investment Management sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 66,635 shares — an estimated $1.24M sold.

MetLife Investment Management first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $1.24M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

MetLife Investment Management reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
MetLife Investment Management sold 66,635 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $1.24M.
MetLife Investment Management first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
MetLife Investment Management's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $1.24M in Q1 2022.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.